CLINICAL TRIALS PROFILE FOR ULORIC
✉ Email this page to a colleague
All Clinical Trials for uloric
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00102440 ↗ | Febuxostat Versus Allopurinol Control Trial in Subjects With Gout | Completed | Takeda | Phase 3 | 2002-07-01 | The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily (QD), versus allopurinol in subjects with gout. |
NCT00174915 ↗ | Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. | Completed | Takeda | Phase 3 | 2003-02-01 | The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout. |
NCT00174941 ↗ | Long-Term Safety of Febuxostat in Subjects With Gout. | Completed | Takeda | Phase 2 | 2001-03-01 | The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD), in maintaining serum urate levels within clinically acceptable levels in subjects with gout. |
NCT00174967 ↗ | Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout | Completed | Takeda | Phase 2 | 2001-01-01 | The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), in reducing serum urate levels in subjects with gout. |
NCT00175019 ↗ | Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 | Completed | Takeda | Phase 3 | 2003-07-01 | The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout. |
NCT00430248 ↗ | Efficacy and Safety of Oral Febuxostat in Participants With Gout | Completed | Takeda | Phase 3 | 2007-02-01 | The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout. |
NCT00995618 ↗ | Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia | Completed | Nuon Therapeutics, Inc. | Phase 2 | 2009-09-01 | This is a randomized, double-blind, 3-period crossover phase 2 study in patients with documented hyperuricemia to evaluate the effect of tranilast on febuxostat pharmacokinetics (PK) and pharmacodynamics (PD) and to evaluate the effect of febuxostat on tranilast PK and PD as measured by reduction in serum uric acid levels. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for uloric
Condition Name
Clinical Trial Locations for uloric
Trials by Country
Clinical Trial Progress for uloric
Clinical Trial Phase
Clinical Trial Sponsors for uloric
Sponsor Name